Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

Sarah BassionyDepartment of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK

Claire N HarrisonDepartment of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK

Donal P McLornanDepartment of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UKCorrespondence[email protected]

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Helen T. Chifotides, Prithviraj Bose & Srdan Verstovsek. (2022) Momelotinib: an emerging treatment for myelofibrosis patients with anemia. Journal of Hematology & Oncology 15:1.
Crossref

Francesco Passamonti, Claire N. Harrison, Ruben A. Mesa, Jean-Jacques Kiladjian, Alessandro M. Vannucchi & Srdan Verstovsek. (2022) Anemia in myelofibrosis: Current and emerging treatment options. Critical Reviews in Oncology/Hematology 180, pages 103862.
Crossref

Massimo Breccia, Giovanni Manfredi Assanto, Alessandro Laganà, Emilia Scalzulli & Maurizio Martelli. (2022) Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors. Current Opinion in Oncology 34:6, pages 729-737.
Crossref

Charlotte EJ. Downes, Barbara J. McClure, Daniel P. McDougal, Susan L. Heatley, John B. Bruning, Daniel Thomas, David T. Yeung & Deborah L. White. (2022) JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies. Frontiers in Cell and Developmental Biology 10.
Crossref

Elena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, Alessandra Iurlo, Ida Carmosino, Giulia Benevolo, Elisabetta Abruzzese, Massimiliano Bonifacio, Micaela Bergamaschi, Nicola Polverelli, Marianna Caramella, Daniela Cilloni, Mario Tiribelli, Novella Pugliese, Giovanni Caocci, Elena Crisà, Raffaele Porrini, Uros Markovic, Rossella Renso, Giuseppe Auteri, Daniele Cattaneo, Malgorzata Monika Trawinska, Luigi Scaffidi, Lucia Biale, Cristina Bucelli, Massimo Breccia, Carlo Gambacorti‐Passerini, Giuseppe Alberto Palumbo, Roberto Latagliata & Francesca Palandri. (2022) Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study. British Journal of Haematology 197:2, pages 190-200.
Crossref

Francesca Palandri, Mario Tiribelli, Massimo Breccia, Daniela Bartoletti, Elena M. Elli, Giulia Benevolo, Bruno Martino, Francesco Cavazzini, Alessia Tieghi, Alessandra Iurlo, Elisabetta Abruzzese, Novella Pugliese, Gianni Binotto, Giovanni Caocci, Giuseppe Auteri, Daniele Cattaneo, Malgorzata M. Trawinska, Rossella Stella, Luigi Scaffidi, Nicola Polverelli, Giorgia Micucci, Elena Masselli, Monica Crugnola, Costanza Bosi, Florian H. Heidel, Roberto Latagliata, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M. Lemoli, Michele Cavo, Nicola Vianelli, Massimiliano Bonifacio & Giuseppe A. Palumbo. (2021) Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer 127:15, pages 2657-2665.
Crossref

Douglas Tremblay & John Mascarenhas. (2021) Next Generation Therapeutics for the Treatment of Myelofibrosis. Cells 10:5, pages 1034.
Crossref

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date